Cortina J M, Martinell J, Artiz V, Fraile J, Rábago G
J Thorac Cardiovasc Surg. 1986 Feb;91(2):174-83.
The intermediate clinical results of 289 patients undergoing isolated mitral valve replacement with three different low-profile mechanical prostheses have been retrospectively analyzed and compared. Between June, 1980, and September, 1983, 70 patients received the Omniscience prosthesis, 159 patients the Medtronic-Hall valve, and 60 patients the convexo-concave 70 degree Björk-Shiley prosthesis. Hospital mortality was 15% for the Björk-Shiley group, 4.4% for the Medtronic-Hall group, and 7.1% for the Omniscience group. Cumulative follow-up was 88 years (mean 1.7 years) for the Björk-Shiley, 229 years (mean 1.5 years) for the Medtronic-Hall, and 223 years (mean 3.3 years) for the Omniscience group. All patients were placed on a program of anticoagulant therapy (dicumarol) postoperatively. Actuarial survival rates (+/-SE) 2 years postoperatively were comparable for the three groups: Björk-Shiley, 90% +/- 4.7%; Medtronic-Hall, 93% +/- 2.2%; and Omniscience, 88% +/- 4.1% (p = NS). Late mortality, expressed at linearized rates (percent patient-year +/-SE), was 3.4% +/- 1.9% for the Björk-Shiley group, 1.7% +/- 0.8% for the Medtronic-Hall group, and 3.6% +/- 1.2% for the Omniscience group (p = NS). Actuarially determined rates of freedom from thromboembolic complications (systemic embolism and valvular thrombosis) 2 years postoperatively were 97% +/- 2.2% for the Björk-Shiley group, 94% +/- 2.1% for the Medtronic-Hall, and 84% +/- 4.7% for the Omniscience group (p = 0.05, Omniscience versus Medtronic-Hall; p = 0.02, Omniscience versus Björk-Shiley) The actuarial probability of being free from reoperation 2 years postoperatively was 92 +/- 3.5 for the Björk-Shiley group, 92 +/- 2.9 for the Medtronic-Hall group, and 82 +/- 3.9 for the Omniscience group (p = 0.04). The major cause for reoperation in the Omniscience group was valve thrombosis (seven patients), yielding a linearized incidence (+/-SE) of 3.1 +/- 1.1 (p = 0.01). No statistically significant differences were obtained regarding the incidence of prosthetic infective endocarditis or perivalvular leak. Overall rates of anticoagulant-related hemorrhage were comparable for the three groups.
对289例接受三种不同低轮廓机械瓣膜单纯二尖瓣置换术患者的中期临床结果进行了回顾性分析和比较。1980年6月至1983年9月期间,70例患者接受了Omniscience瓣膜,159例患者接受了Medtronic-Hall瓣膜,60例患者接受了凸凹70度Björk-Shiley瓣膜。Björk-Shiley组的医院死亡率为15%,Medtronic-Hall组为4.4%,Omniscience组为7.1%。Björk-Shiley组的累积随访时间为88年(平均1.7年),Medtronic-Hall组为229年(平均1.5年),Omniscience组为223年(平均3.3年)。所有患者术后均接受抗凝治疗(双香豆素)方案。术后2年的精算生存率(±标准误)在三组中具有可比性:Björk-Shiley组为90%±4.7%;Medtronic-Hall组为93%±2.2%;Omniscience组为88%±4.1%(p=无显著性差异)。以线性化率(每患者年百分比±标准误)表示的晚期死亡率,Björk-Shiley组为3.4%±1.9%,Medtronic-Hall组为1.7%±0.8%,Omniscience组为3.6%±1.2%(p=无显著性差异)。术后2年精算确定的无血栓栓塞并发症(全身性栓塞和瓣膜血栓形成)发生率,Björk-Shiley组为97%±2.2%,Medtronic-Hall组为94%±2.1%,Omniscience组为84%±4.7%(Omniscience组与Medtronic-Hall组比较,p=0.05;Omniscience组与Björk-Shiley组比较,p=0.02)。术后2年无再次手术的精算概率,Björk-Shiley组为92±3.5,Medtronic-Hall组为92±2.9,Omniscience组为82±3.9(p=0.04)。Omniscience组再次手术的主要原因是瓣膜血栓形成(7例患者),线性化发生率(±标准误)为3.1±1.1(p=0.01)。关于人工瓣膜感染性心内膜炎或瓣周漏的发生率,未获得统计学上的显著差异。三组抗凝相关出血的总体发生率具有可比性。